Physician profile
Jack H Hunt
NPI 1639148489
$353.85
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $42.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $76.59 | 2019-2020 | |
| Novo Nordisk INC | $58.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.67 | 2019 | |
| Merck Sharp & Dohme LLC | $39.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.17 | 2019-2020 | |
| Radius Health, INC. | $20.93 | 2019 | |
| Astellas Pharma US INC | $20.93 | 2019 | |
| Shire North American Group INC | $15.25 | 2019 | |
| Lilly USA, LLC | $14.98 | 2019 | |
| Gilead Sciences, INC. | $13.02 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.